Skip to main content
E

Energenesis Biomedical CO.,LTD. — Investor Relations & Filings

Ticker · 6657 TW Professional, scientific and technical activities
Open in API
Filings indexed 28 across all filing types
Latest filing 2026-04-21 AGM Information
Country TW Taiwan
Listing TW 6657

About Energenesis Biomedical CO.,LTD.

http://www.energenesis-biomedical.com

Energenesis Biomedical Co., Ltd. specializes in the research and development of innovative pharmaceuticals through its proprietary ENERGI drug development platform. The company focuses on the activation of AMP-activated protein kinase (AMPK), a critical enzyme for cellular energy regulation, to develop therapeutic solutions for various diseases. Its core pipeline centers on small molecule purine compounds designed to modulate cellular energy metabolism. Operating with an intellectual property-driven strategy, the company manages the development cycle from early-stage drug discovery through clinical trial validation. Energenesis Biomedical aims to increase the value of its proprietary technologies for strategic out-licensing and collaboration with global pharmaceutical partners. In addition to drug development, the company offers specialized testing and analysis services and distributes research reagents.

Recent filings

Filing Released Lang Actions
115年年報及股東會資料 — 2026_6657_20260522FE2.pdf
AGM Information Classification · 1% confidence The document is titled "2026 Annual General Shareholders' Meeting Handbook" and includes the full meeting procedures, agenda, report items, proposal items, attachments (business report, audit report, financial statements, amendments to governing documents, share repurchase details, private placement plan, etc.)—all materials prepared for and used at the Annual General Meeting. This matches the definition of AGM Information (AGM-R).
2026-04-21 English
115年年報及股東會資料 — 2026_6657_20260522F02.pdf
Regulatory Filings
2026-04-21 Chinese
115年年報及股東會資料 — 2026_6657_20260522FE1.pdf
Regulatory Filings
2026-04-21 Chinese
115年年報及股東會資料 — 2026_6657_20260522F01.pdf
Regulatory Filings
2026-04-21 Chinese
本公司董事會決議發行限制員工權利新股
Share Issue/Capital Change Classification · 1% confidence The document is an official Market Observation Post System announcement by a listed company regarding a board resolution to issue new restricted shares to employees. It details share issuance price, number of shares, vesting conditions, impact on EPS, and other issuance terms. This is a corporate announcement of a new share issue (capital change), matching the "Share Issue/Capital Change" category.
2026-04-10 Chinese
公告本公司董事會決議通過對子公司源華智醫股份有限公司 得分次辦理對該子公司釋股作業
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory announcement filed by the company on the public information observatory (公開資訊觀測站) describing a board resolution to handle the subscription and disposal (“釋股”) of shares in its subsidiary (源華智醫), including mechanisms for capital increase, waiver of subscription, and share sales. This is clearly an announcement of share-related capital changes (capital increase/subscription decisions and share disposal) rather than a full financial report or other category. Therefore it best fits the “Share Issue/Capital Change” category (SHA).
2026-04-10 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.